{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-199383","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.008636+00:00","generated_at":"2026-05-31T09:50:29.326077+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech Q2 net loss $20.7M; cash runway into Q4 2025; Phase 3 interim analysis expected Q3 2024","bullets":["Net loss of $20.7M for Q2 2024 vs $21.2M in Q2 2023; R&D expenses $15.8M.","Cash and equivalents $100.7M at June 30, 2024, down from $143.2M at year-end 2023.","Phase 3 trial (IOB-013) interim analysis for ORR expected Q3 2024; primary PFS endpoint in H1 2025.","Potential BLA submission in Q4 2024 if interim analysis supports accelerated approval.","Completed enrollment in Phase 2 basket trial (IOB-022) for NSCLC and SCCHN; data to be presented at ESMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-199383","json":"https://secwatch.observer/filing/0001193125-24-199383.json","markdown":"https://secwatch.observer/filing/0001193125-24-199383.md","text":"https://secwatch.observer/filing/0001193125-24-199383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524199383/0001193125-24-199383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524199383/d894513d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:50:29.326077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}